-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Hangzhou, Shaoxing, and Suzhou, China, November 8, 2021/PRNewswire/ ---Gallery Pharmaceutical Co.
Under the terms of the agreement, Corning Jerry Suzhou song ceremony to grant the development and commercialization ASC22 outside Greater China exclusive worldwide rights, authorized indications for all viral diseases, including hepatitis B, including
Together with the exclusive development agreement for Greater China jointly announced by Songli and Suzhou Corning Jerry on January 14, 2019 (see press release for details: https:// Suzhou Jerry Corning has been granted for the treatment of the song ceremony ASC22 exclusive worldwide development and commercialization rights and interests of all viral diseases, including hepatitis B, including
ASC22 is an immunotherapy with the fastest progress in clinical research and development in the world by blocking the PD-1/PD-L1 signaling pathway for the functional cure of chronic hepatitis B (ie, the disappearance of hepatitis B surface antigen)
ASC22 is currently undergoing a phase IIb clinical trial in China.
Dr.
About songli
Gale is an innovative R&D-driven biotechnology company listed on the Hong Kong Stock Exchange (1672.
1.
Source: Golly Pharmaceutical Co.